The effect of casirivimab with imdevimab on disease progression in nonsevere COVID-19 patients in a single hospital in Japan.

The effect of casirivimab with imdevimab on disease progression in nonsevere COVID-19 patients in a single hospital in Japan. - The effect of casirivimab with imdevimab on disease progression in nonsevere COVID-19 patients in a single hospital in Japan.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000045358

Enrollment

400

Registered

2021-09-02

Start date

2021-08-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infectious disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who meet all the following criteria will be eligible. (1)The patient age is 18 years old. (2)COVID-19 is diagnosed based on nucleic acid tests or antigen tests. (3)The duration of COVID-19 symptoms is less than 7 days. (4)The patient has at least one risk factor. (5)Fever associated with COVID-19 is documented within 24 hours before admission or during hospitalization.

Exclusion criteria

Exclusion criteria: Patients whose symptoms started more than 14 days after the second COVID-19 vaccination were excluded. Patients who required oxygen therapy due to persistent hypoxia at admission were also excluded.

Design outcomes

Primary

Measure	Time frame
(1) Disease progression to severe COVID-19. Severe COVID-19 is defined as patients requiring oxygen therapy and dexamethasone. (2) Composite outcome that includes critical care needs and in-hospital death.	—

Countries

Japan

Contacts

Public ContactJunpei Komagamine

National Hospital Organization Tochigi Medical Center Internal Medicine

jkomagamine@tochigi-mc.jp028-622-5241

Outcome results